A Phase 3 interventional study of Omeprazole, amoxicillin, clarithromycin and Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole in Helicobacter Infections, sponsored by Forest Laboratories. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-16.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication. It is hypothesized that quadruple therapy will be comparable in efficacy to triple therapy. Subjects with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 6 and 10 follow-up visits, a urea breath test (UBT) will be performed to confirm eradication.
The study will include three phases: screening, treatment and follow-up. Screening: this phase will last a maximum of 30 days and subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.
Treatment: Subjects assigned to OAC will be treated for 7 days. Those assigned to Pylera will be treated for 10 days. A randomization visit will take place on Day 0 and an end-of-treatment visit will take place between day 8 and 14.
Follow-up: includes two visits. approximately one and two months post-treatment. Eradication of H. Pylori will be confirmed through UBT, and resistance will be evaluated in case of treatment failure. These subjects will undergo an endoscopy.
53 studies on the registry are indexed under Helicobacter Infections; 9 are open to participants now.
This study's enrollment of 440 is above the median of 216 across 34 interventional studies indexed under Helicobacter Infections.
Browse Helicobacter Infections studies →Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
First submitted before Forest Laboratories became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
Drug: Omeprazole, amoxicillin, clarithromycin
OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
Drug: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
Drug pages: Omeprazole · Amoxicillin · Clarithromycin
Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
Also known as: Pylera
Helicobacter Pylori Eradication Confirmed by Urea Breath Test
H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits.
Time frame: Week 6 and week 10 follow-up visits
Number of Patients Experiencing Treatment Emergent Adverse Events.
A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation. All safety analysis based on the safety population.
Time frame: at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits.
H. Pylori Eradication and Presence or Past History of Peptic Ulcers
Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows.
Time frame: Week 6 and week 10 follow-up visits
Clarithromycin Resistance
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above
Time frame: Measured at baseline
Metronidazole Resistance
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml
Time frame: Measured at baseline
Overall Compliance to Study Medications
Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population
Time frame: At the end of the treatment phase (days 8-14)
Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level
Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter)
Time frame: Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only
First patient in: 11 June 2008 Last patient out: 22 June 2009 Patients were recruited from clinics and hospitals located in seven European Countries: Germany, Poland, Italy, France, Ireland, Spain, United Kingdom.
| Milestone | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Started | 218 | 222 |
| Completed | 204 | 195 |
| Not completed | 14 | 27 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 5 | 7 |
| Withdrew: Protocol violation | 2 | 7 |
| Withdrew: Investigator sponsor judgement | 0 | 1 |
| Withdrew: Not compliant with study drug/visit | 2 | 3 |
H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits.
| Participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Helicobacter Pylori Eradication Confirmed by Urea Breath Test | 166 | 112 |
A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation. All safety analysis based on the safety population.
| Participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Number of Patients Experiencing Treatment Emergent Adverse Events. | 101 | 112 |
Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows.
| Participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| H. Pylori Eradication and Presence or Past History of Peptic Ulcers | 18 | 15 |
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above
| participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Clarithromycin Resistance | 30 | 2 |
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml
| participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Metronidazole Resistance | 38 | 28 |
Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population
| participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Overall Compliance to Study Medications | 97.58 ± 10.71 | 97.47 ± 14.91 |
Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter)
| participants | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level | 0 | — |
Collected over Adverse events were recorded starting at the signing of the informed consent until the final visit (Day 70) or early withdrawal visit. Serious adverse events were followed until 30 days after the patient had stopped study participation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quadruple Therapy (OBMT) 10 Days | — | 4/216 (1.9%) | 98/216 (45.4%) |
| Triple Therapy (OAC) 7 Days | — | 3/222 (1.4%) | 105/222 (47.3%) |
| Event | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| EczemaSkin and subcutaneous tissue disorders | 1/216 | 0/222 |
| Gastrointestinal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/216 | 0/222 |
| Proteus infectionInfections and infestations | 1/216 | 0/222 |
| Renal artery stenosisRenal and urinary disorders | 1/216 | 0/222 |
| Renal failure acuteRenal and urinary disorders | 1/216 | 0/222 |
| SchizophreniaPsychiatric disorders | 1/216 | 0/222 |
| e coli urinary tract infectionInfections and infestations | 1/216 | 0/222 |
| AppendicitisInfections and infestations | 0/216 | 1/222 |
| Condition aggravatedGeneral disorders | 0/216 | 1/222 |
| DehydrationMetabolism and nutrition disorders | 0/216 | 1/222 |
| Event | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days |
|---|---|---|
| DyspepsiaGastrointestinal disorders | 22/216 | 30/222 |
| DiarrheaGastrointestinal disorders | 14/216 | 28/222 |
| DysgeusiaNervous system disorders | 12/216 | 22/222 |
| Abdominal pain upperVascular disorders | 18/216 | 16/222 |
| HeadacheGastrointestinal disorders | 18/216 | 7/222 |
| NauseaGastrointestinal disorders | 14/216 | 2/222 |
| Age, Categorical(Participants) | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 184 | 194 | 378 |
| >=65 years | 34 | 28 | 62 |
| Age, Continuous(years) | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days | Total |
|---|---|---|---|
| Mean | 48.53 ± 14.64 | 47.95 ± 14.52 | 48.24 ± 14.58 |
| Sex: Female, Male(Participants) | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days | Total |
|---|---|---|---|
| Female | 105 | 100 | 205 |
| Male | 113 | 122 | 235 |
| Region of Enrollment(participants) | Quadruple Therapy (OBMT) 10 Days | Triple Therapy (OAC) 7 Days | Total |
|---|---|---|---|
| Italy | 10 | 10 | 20 |
| Spain | 7 | 6 | 13 |
| France | 15 | 17 | 32 |
| Germany | 92 | 91 | 183 |
| Poland | 91 | 93 | 184 |
| United Kingdom | 3 | 5 | 8 |
The record gives a start of Jun 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.